News - Versant Ventures

Nexo Therapeutics Launches With $60 Million Series A Financing. Download PDF. read more. Apr 20, 2023 ... 858 Therapeutics Launches with Proven Team and $60 Million Series A …

CouponFollow Extension

$60
OFF

News - Versant Ventures

6 days from now

Nexo Therapeutics Launches With $60 Million Series A Financing. Download PDF. read more. Apr 20, 2023 ... 858 Therapeutics Launches with Proven Team and $60 Million Series A …

versantventures.com

$60
OFF

News | 858 Therapeutics

6 days from now

September 21, 2021 858 Therapeutics Launches with Proven Team and $60 Million Series A Financing. September 21, 2021 Bristol Myers, Genentech and Celgene bought their old …

8five8tx.com

$60
OFF

San Diego Biotech Uncloaks With $60 Million To Tackle ... - BioSpace

6 days from now

Sep 21, 2021 · A San Diego-based biotech has exited stealth mode with hopes of treating cancers that are resistant to current therapies. On Tuesday, 858 Therapeutics launched with a …

biospace.com

$60
OFF

858 Therapeutics Launches With Proven Team And $60 Million

6 days from now

Sep 21, 2021 · 858 Therapeutics today exited stealth mode with a $60 million Series A financing led by founding investor Versant Ventures. Sept. 21, 2021 12:00 UTC. -- Serial entrepreneurs …

biospace.com

$60
OFF

News | 858 Therapeutics Launches With Proven Team And $60 …

6 days from now

Sep 21, 2021 · Team; Portfolio; Offices; News; ← View News. Sep 21, 2021 858 Therapeutics Launches with Proven Team and $60 Million Series A Financing. Download PDF. Media …

versantventures.com

$60
OFF

858 Therapeutics Launches With Proven Team And $60 Million …

6 days from now

Sep 21, 2021 · SAN DIEGO, CA, USA I September 21, 2021 I 858 Therapeutics today exited stealth mode with a $60 million Series A financing led by founding investor Versant Ventures, …

pipelinereview.com

$60
OFF

858 Therapeutics Launches With Proven Team And $60 Million

6 days from now

Sep 21, 2021 · SAN DIEGO-- ( BUSINESS WIRE )-- 858 Therapeutics, Inc. today exited stealth mode with a $60 million Series A financing led by founding investor Versant Ventures, with …

biospace.com

$60
OFF

A Financing 858 Therapeutics Launches With Proven Team And …

6 days from now

858 Therapeutics Launches with Proven Team and $60 Million Series A Financing. lism and innate immunity --September 21, 2021 08:00 AM Eastern Daylight TimeSAN DIEGO- …

versantventures.com

$60
OFF

858 Therapeutics Launches With Proven Team And $60 Million …

6 days from now

Sep 21, 2021 · Share this Story : 858 Therapeutics Launches with Proven Team and $60 Million Series A Financing

financialpost.com

$60
OFF

858 Therapeutics : Launches With Proven Team And $60 Million …

6 days from now

Sep 21, 2021 · -- Serial entrepreneurs Jeff Stafford, Jim Veal, Gretchen Bain form another San Diego-based discovery company with Versant Ventures -- -- Lead cancer drug discovery …

marketscreener.com

$60
OFF

Series A - 858 Therapeutics - 2021-09-21 - Crunchbase

6 days from now

Sep 21, 2021 · News — 858 Therapeutics Launches with Proven Team and $60 Million Series A Financing . ... BioSpace — 858 Therapeutics Launches with Proven Team and $60 Million …

crunchbase.com

$60
OFF

858 Therapeutics Launches With Proven Team And $60 Million …

6 days from now

SAN DIEGO--(BUSINESS WIRE)-- 858 Therapeutics today exited stealth mode with a $60 million Series A financing led by founding investor Versant Ventures, with participation from NEA, …

creditriskmonitor.com

$60
OFF

858 Therapeutics Acquires Gotham Therapeutics - 2021-09-21

6 days from now

Business Wire — 858 Therapeutics Launches with Proven Team and $60 Million Series A Financing . News • Sep 20, 2021. Chemical & Engineering News — 858 Therapeutics …

crunchbase.com

$60
OFF

858 Therapeutics Launches With Proven Team And $60 Million …

6 days from now

On September 21, 2021 858 Therapeutics reported that stealth mode with a $60 million Series A financing led by founding investor Versant Ventures, with participation from NEA, Cormorant …

1stoncology.com

$60
OFF

858 Therapeutics | Portfolio | Versant Ventures

6 days from now

858 Therapeutics Launches with Proven Team and $60 Million Series A Financing. LP Access.

versantventures.com

FAQs about News - Versant Ventures Coupon?

What happened to 858 Therapeutics?

SAN DIEGO-- ( BUSINESS WIRE )--858 Therapeutics today exited stealth mode with a $60 million Series A financing led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital. ...

Has 858 Therapeutics acquired Gotham Therapeutics?

858 Therapeutics has acquired Gotham Therapeutics, based in New York City, for an undisclosed sum. Gotham is focused on epitranscriptomics, the study of chemical modifications of RNA. In addition to its own drug discovery programs, 858’s pipeline will get a boost through this acquisition. ...

Who are the founders of 858?

858’s founding team includes CEO Jeffrey Stafford, Ph.D., CSO James Veal, Ph.D., and VP of Biology Gretchen Bain, Ph.D. They previously held leadership roles at three other San Diego-based discovery companies co-founded by Versant including Jecure Therapeutics, Quanticel Pharmaceuticals and Amira Pharmaceuticals. ...

Is 858 a good company to invest in RNA modification?

“We are confident that 858 is well-positioned to capitalize on recent scientific discoveries in the field of RNA modification and translate them into a pipeline of drug candidates,” said Clare Ozawa, Ph.D., Managing Director at Versant and an 858 board member. ...

What is a series a grant for 858?

The Series A proceeds will allow 858 to enter the clinic with its lead candidates that have potential to treat cancers that are resistant to current therapies. 858 is headquartered in San Diego and will maintain lab operations both in San Diego and New York City. ...

Will funding help 858's METTL3 program in 2023?

The financing for 858 Therapeutics should help advance their lead programs, including the METTL3 program from Gotham, into the clinic by 2023.\nStafford says... Gotham was based on the work of its cofounder Samie Jaffrey, a scientist at Weill Cornell Medicine. Jaffrey is now an advisor to 858. ...